Erik Bloomquist and Maria Kudela
Judy Li serves as the head of hematology strategy for late oncology statistics at AstraZeneca, where she provides leadership and expertise in oncology statistics. Her work emphasizes strategic planning, technical oversight, functional development, and operational guidance. Throughout her career, Li has held senior leadership positions in both the biopharmaceutical and biotech sectors, making contributions at organizations including Bristol Myers Squibb, Celgene, and Regeneron Pharmaceuticals. Prior to her industry tenure, she garnered extensive experience at the US Food and Drug Administration as a master statistical reviewer and supervisory mathematical statistician. She has clinical development experience across multiple therapeutic areas—including oncology, hematology, immunology, neurology, and cell therapy—and experience in special clinical settings for multiregional clinical trials and rare disease.
Li has been an active member of the American Statistical Association Biopharmaceutical Section Executive Board for more than a decade. She has taken on various roles, including co-founding the Safety Monitor Working Group and chairing the 2019 Regulatory Industry Statistics Workshop, along with chairing the poster competition section and membership committee. She also serves on the board of directors and the advisory council of the Bay Area Biotech-Pharma Statistics Workshop. Additionally, she is an editor of the book Quantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation. Her research has been acknowledged by the FDA Office of Chief Scientist and received the Intramural Grant award for two consecutive years.
In 2023, Judy decided to return to school at The Wharton School to pursue an executive MBA in strategic management with a focus on the health care industry. We asked her about this decision and its impact on her career thus far, as well as whether she has any advice for statisticians considering a similar move.
What motivated you to go back to school at this point in your career?
I frequently receive this question, and I appreciate the opportunity to share my journey here.
Returning to school after more than 15 years in the workforce was a significant decision for me. In today’s rapidly evolving landscape, particularly with the rise of technology and AI, the role of statisticians in the pharmaceutical industry is continually transforming. As the emphasis on big data grows, statisticians are assuming increasingly critical roles in the decision-making process. I realized that just having technical skills wouldn’t be enough to make a real impact. A deeper understanding of business, economics, and the operational aspects underlying decisions has become essential. This knowledge is crucial for turning data and insights into meaningful, data-driven decisions.
I also think a lot about how we can develop our talent and support the next generation of statisticians as they face their own challenges. It became clear to me that enhancing soft skills is essential, particularly in areas such as effective communication as a leader, efficient management of a large global team, and the creation of a welcoming environment for diverse employees.
That’s why an MBA program seemed like the perfect opportunity to get the structured training I needed in these areas. It not only boosted my business knowledge but also helped me build the leadership skills to inspire and guide others in this fast-paced field. Going for an executive MBA felt like the right move to reach my potential and make a positive impact in my organization and beyond, and I’m really glad I made that choice.
What drew you to pursuing an MBA, rather than another program?
I decided to pursue my MBA at Wharton, recognized as one of the top business schools globally. What drew me to the executive MBA program there is that its curriculum is just as rigorous and comprehensive as the full-time MBA. The only difference is classes are scheduled on weekends. My focus on strategic management with a concentration in the health care industry fits perfectly with my current role and my passion for making a positive impact in the health care field.
How did you think this program would impact your current career path or new opportunities? Were your expectations met after you graduated? Do you think the experience has been beneficial for your career?
Absolutely—more than 100%! The MBA experience has significantly broadened my mindset, integrating disciplines such as global economy, finance, operations, technology, and communications into my daily work, all while focusing on cultural leadership. It has given me a clearer perspective on tackling challenges and creating value, helping me become a more effective strategic leader capable of making executive-level, data-driven decisions—not just for the business but for the patients who rely on our innovations.
Additionally, the relationships I’ve built through the Wharton network have been incredibly rewarding. Collaborating with talented individuals from diverse fields like tech, finance, and consulting has provided fresh perspectives that are crucial for a holistic approach to leadership. This collaborative environment has inspired me to think creatively and strategically, pushing me to explore my full potential.
I would also like to highlight that the impact of an MBA goes beyond just career advancement; it has shaped my overall outlook on life. I’ve become more strategic, value-driven, and rational in my thinking. For example, in my finance valuation class, our professor shared a powerful philosophy: A tree knows not to grow branches where there is no sunlight, much like how individuals and businesses should focus on opportunities that provide returns greater than their opportunity costs. Insights like this have been a recurring theme throughout nearly every lecture, and I believe these lessons will provide lifelong benefits.
How did you balance school with your other responsibilities, such as work and personal life?
This question often arises during MBA interviews because admissions committees understand that pursuing an MBA involves significant challenges that demand a strong commitment to succeed. Depending on the individual, an MBA program can require anywhere from 20–40 hours each week, which inevitably limits the time available for family and may occasionally result in missed workdays. Sleep is often compromised, as well. It is vital to have open and proactive discussions with family, managers, and colleagues about these commitments prior to beginning the program. Establishing a supportive network is essential for effectively managing the challenges of an executive MBA.
I feel fortunate to have a very supportive employer and a strong supporting family and network throughout this journey.
How was the application process? Did you find it difficult?
The application process was quite straightforward. The primary requirement for most schools is either the GMAT or an executive evaluation test for admission, which necessitates some preparation. Since the program emphasizes a strong quantitative background, having a degree in statistics or mathematics can give you a significant competitive edge during the application process 😊.
Any advice or tips for those who are considering an MBA or another program?
Understanding your priorities is crucial. What matters most to you right now? Going back to school may not be the right choice for everyone. However, for those who have thought it through and decided to pursue an MBA or another program, my advice is to do it sooner rather than later. The learning experience in these programs is intense and filled with valuable insights. Many people find it takes years after graduation to fully absorb what they’ve learned and apply it in real-life situations. The benefits of this education can have a lasting impact, so starting earlier allows you to take advantage of the skills and knowledge you acquire right away.
Anything else you would like to share with our audience?
As Benjamin Franklin said, “An investment in knowledge always pays the best interest.”
Chase your dreams fearlessly, engage in lifelong learning, and strive to make a difference. Remember, the sky is the limit!
Editor’s note: This article originally ran in the 2025 spring issue of the Biopharmaceutical Report and is republished with permission.
Leave a Reply